What is Leerink Partnrs’ Forecast for ANIP Q1 Earnings?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for ANI Pharmaceuticals in a report issued on Wednesday, April 9th. Leerink Partnrs analyst F. Khurshid forecasts that the specialty pharmaceutical company will post earnings per share of $0.91 for the quarter. The consensus estimate for ANI Pharmaceuticals’ current full-year earnings is $3.86 per share. Leerink Partnrs also issued estimates for ANI Pharmaceuticals’ Q2 2025 earnings at $1.27 EPS, Q3 2025 earnings at $1.23 EPS, Q4 2025 earnings at $1.50 EPS, FY2025 earnings at $4.90 EPS and FY2026 earnings at $5.43 EPS.

Several other research analysts have also recently issued reports on ANIP. Guggenheim reaffirmed a “buy” rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Friday. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price for the company. Finally, Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $68.12 on Friday. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $70.00. The firm’s 50-day moving average is $62.34 and its 200 day moving average is $59.07. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of -123.85 and a beta of 0.49. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Institutional Investors Weigh In On ANI Pharmaceuticals

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of ANI Pharmaceuticals by 14.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after buying an additional 1,972 shares during the period. Geode Capital Management LLC raised its stake in shares of ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after buying an additional 17,314 shares during the period. Franklin Resources Inc. lifted its position in shares of ANI Pharmaceuticals by 6.1% during the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after buying an additional 691 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of ANI Pharmaceuticals by 1,681.2% during the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after acquiring an additional 135,003 shares during the period. Institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 3,200 shares of company stock worth $191,776. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.